Drug Trial Radar · NCT06722950
Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy
Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, multicenter, Phase II clinical study of AC591 in preventing Oxaliplatin-Induced Peripheral Neuropathy
Conditions
- Colorectal Adenoma
Interventions
CAPEOXDrug
CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
PlaceboDrug
Placebo:3 times a day (daily), taken with boiled water.
AC591Drug
AC591 : 3 times a day (daily), taken with boiled water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with grade 1-3 oxaliplatin-induced peripheral neuropathy as assessed by the oxaliplatin-specific Levi rating toolTime frame: At the end of Cycle 4 (each cycle is 21 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.